Camblong Jurgi sold $298K of SOPH
Camblong Jurgi (Chief Executive Officer) sold 51,442 shares of SOPHiA GENETICS SA (SOPH) at an average of $5.80 ($5.70–$5.84, $0.30M total) across 3 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s scheduled open-market sale totals ~$298k across three trades at an average ~$5.80, with holdings after the sale reported at 3,601,493 shares.
Market read
Traders may briefly reassess sentiment around SOPH due to insider selling optics, but the 10b5-1 framing limits fundamental read-through.
What to watch
The filing does not disclose any new operational, financial, or regulatory information—only the transaction details—so the main tradable element is sentiment/positioning rather than fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS (SOPH).
Ticker impact
SEC Form 4 shows CEO Camblong Jurgi sold 51,442 shares of SOPHiA GENETICS at ~$5.70–$5.84 (total ~$298k) under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this disclosure; any impact is likely short-lived.
The filing is a disclosed open-market sale by the CEO, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no sector-wide catalyst.
None indicated; SOPHiA GENETICS is the only subject.
None indicated; no deal, regulation, or operational change described.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals, so traders may ignore it for directional bias.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction; CEO Camblong Jurgi sold shares under a 10b5-1 plan.
- insiderCamblong Jurgi
CEO and officer/director who executed the open-market sale.
